Please login to the form below

Not currently logged in
Email:
Password:

Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial

Results showing that the drug is an improvement on Xalkori were released at ESMO 2020 virtual congress

Pfizer’s Lorbrena has come out on top in a head-to-head trial against its older ALK inhibitor Xalkori in previously untreated non-small cell lung cancer (NSCLC) with this specific genetic mutation.

Lorbrena (lorlatinib) reduced the risk of disease progression or death by 72% in ALK-positive NSCLC patients compared to Xalkori (crizotinib) in the phase 3 CROWN trial, presented over the weekend at the 2020 European Society for Medical Oncology (ESMO) virtual congress.

In the same trial, the progression-free survival rate was not yet estimable for Lorbrena, compared to 9.3 months for Xalkori. The intracranial objective response rate was 82% in patients with measurable brain metastases, with a complete response rate of 71% associated with Lorbrena treatment.

Despite the NSCLC market being largely dominated by Merck & Co/MSD’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in around 3-5% of all cases.

Follow-up ALK inhibitors are particularly crucial in this treatment setting, given that many patients experience tumour progression after initial treatment and often require a second- or third-line option. It is also important to note that central nervous system progression often occurs in this type of cancer, wherein the cancer spreads to the brain.

“These results of the CROWN study support the use of Lorbrena as a highly effective first-line therapy for patients with advanced ALK-positive non–small cell lung cancer,” said lead study author Ben Solomon, a medical oncologist in the Lung Service and the Head and Neck service.

The company added that it also intends to share the results from the study with the US Food and Drug Administration (FDA) and other health regulators across the globe to support its approval ambitions.

Currently, Lorbrena is approved only in the second-line setting, for patients who have already been treated with one or more therapies, including Xalkori and treatments from other competitors.

Article by
Lucy Parsons

21st September 2020

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...